Secondary Logo

Journal Logo

1.5 CE Test Hours

HIV Update

An Epidemic Transformed

Contrada, Emily

AJN The American Journal of Nursing: September 2019 - Volume 119 - Issue 9 - p 40
doi: 10.1097/01.NAJ.0000580160.35570.cf
Feature Articles
Free
CE
Back to Top | Article Outline

TEST INSTRUCTIONS

  • Read the article. Take the test for this CE activity online at www.nursingcenter.com/ce/ajn.
  • You'll need to create and log in to your personal CE Planner account before taking online tests. Your planner will keep track of all your Lippincott Professional Development (LPD) online CE activities for you.
  • There is only one correct answer for each question. The passing score for this test is 14 correct answers. If you pass, you can print your certificate of earned contact hours and the answer key. If you fail, you have the option of taking the test again at no additional cost.
  • For questions, contact LPD: 1-800-787-8985.
  • Registration deadline is September 3, 2021.
Back to Top | Article Outline

PROVIDER ACCREDITATION

  • LPD will award 1.5 contact hours for this continuing nursing education (CNE) activity. LPD is accredited as a provider of CNE by the American Nurses Credentialing Center's Commission on Accreditation.
  • This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1.5 contact hours. LPD is also an approved provider of CNE by the District of Columbia, Georgia, and Florida #50-1223. Your certificate is valid in all states.
Back to Top | Article Outline

PAYMENT

  • The registration fee for this test is $17.95.
Back to Top | Article Outline

UNDERSTANDING THE COMPLICATIONS OF SICKLE CELL DISEASE

GENERAL PURPOSE:

To provide information about HIV epidemiology, the current state of HIV treatment and prevention, and common comorbidities of people living with HIV (PLWH) who are over age 50.

Back to Top | Article Outline

LEARNING OBJECTIVES/OUTCOMES:

After completing this continuing education activity, you should be able to

  • describe the current epidemiology data for PLWH.
  • summarize the available options for treating HIV infection.
  • explain the comorbidity risks and protocols for both pre- and postexposure HIV prophylaxis.
  1. The vast majority of women who have HIV infection acquired it through
    1. homosexual sex.
    2. heterosexual sex.
    3. unsafe injection practices.
  2. According to the Centers for Disease Control and Prevention, which of the following racial or ethnic groups had the highest incidence of HIV infection in 2015?
    1. blacks
    2. whites
    3. Hispanics or Latinos
  3. Despite a decline in overall incidence of HIV infection, incidence has increased in which of the following racial or ethnic groups?
    1. Eastern Europeans
    2. blacks
    3. Asians
  4. Hess and colleagues reported that the estimated lifetime risk of acquiring HIV is 1 in 5 among men who have sex with men in which of the following ethnic groups?
    1. blacks
    2. whites
    3. Hispanics or Latinos
  5. In 2016, adults in which of the following age groups accounted for the largest percentage of new HIV infections in the United States and its 6 dependent areas?
    1. 20 through 29 years
    2. 30 through 49 years
    3. 50 years and older
  6. At the end of 2016, which of the following countries had achieved the 90–90–90 targets of the Joint United Nations Programme on HIV/AIDS?
    1. Norway
    2. Cambodia
    3. the United States
  7. According to 2018 U.S. Department of Health and Human Services guidelines, antiretroviral therapy (ART) is now recommended
    1. when CD4+ cell counts are below 350 cells/mm3.
    2. when the viral load is more than 250 copies/mL.
    3. regardless of CD4+ cell count or viral load.
  8. Initially for most PLWH, ART has included 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) plus a drug from another class, usually
    1. a nonnucleoside reverse transcriptase inhibitor (NNRTI).
    2. an integrase strand transfer inhibitor (INSTI).
    3. a protease inhibitor.
  9. The first NRTI-sparing, single-tablet regimen approved by the U.S. Food and Drug Administration (FDA) as a replacement ART for PLWH whose viral loads were undetectable combines dolutegravir with
    1. rilpivirine.
    2. doravirine.
    3. etravirine.
  10. Which of the following is one of the 2 most common pharmacokinetic boosting agents used to reduce dosing frequency, often to once a day?
    1. tipranavir
    2. cobicistat
    3. maraviroc
  11. The most common adverse effect of the CD4-directed postattachment HIV-1 inhibitor ibalizumab is
    1. fatigue.
    2. pyrexia.
    3. diarrhea.
  12. The newest FDA-approved medication for treating HIV infection is a single-tablet regimen that combines dolutegravir with
    1. stavudine.
    2. lamivudine.
    3. emtricitabine.
  13. Compared with other NRTIs, which medication in that class has been associated with higher rates of cardiovascular events?
    1. abacavir
    2. didanosine
    3. tenofovir alafenamide
  14. According to Coelho and colleagues, which of the following diagnostic tests may be most accurate in identifying type 2 diabetes in PLWH?
    1. glycated hemoglobin test
    2. oral glucose tolerance testing
    3. serial fasting blood glucose monitoring
  15. According to Engels and colleagues, besides the AIDS-defining cancers such as Kaposi sarcoma and non-Hodgkin lymphoma, lung cancer and which other type of cancer account for a large proportion of cancer-related deaths in PLWH?
    1. gastric
    2. kidney
    3. liver
  16. Which of the following treatment options remains the greatest protection against HIV-associated neurocognitive disorder?
    1. ART
    2. exercise
    3. memantine
  17. Currently, the only FDA-approved form of preexposure prophylaxis for HIV is a single-tablet regimen containing the NRTIs tenofovir disoproxil fumarate and
    1. abacavir.
    2. zidovudine.
    3. emtricitabine.
  18. Postexposure prophylaxis (PEP) involves
    1. taking ART for 48 days following HIV exposure.
    2. initiating treatment no more than 72 hours after HIV exposure.
    3. taking tenofovir alafenamide and lamivudine with an entry inhibitor.
  19. After conducting baseline laboratory studies upon initiating PEP, monitoring and follow-up HIV testing is recommended at 4 weeks and again at how many weeks after treatment begins?
    1. 12
    2. 16
    3. 20
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.